

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY	1
SCOPE OF REPORT	1
INTENDED AUDIENCE.....	2
METHODOLOGY	2
RELATED BCC STUDIES	2
ANALYST CREDENTIALS.....	3
BCC ONLINE SERVICES.....	3
DISCLAIMER	3
 CHAPTER TWO: SUMMARY.....	 4
SUMMARY.....	4
<i>SUMMARY TABLE GLOBAL MARKET FOR RNAI DRUG DELIVERY</i> <i>TECHNOLOGIES, THROUGH 2015 (\$ MILLIONS)</i>	 5
<i>SUMMARY FIGURE GLOBAL MARKET FOR RNAI DRUG DELIVERY</i> <i>TECHNOLOGIES, 2009–2015 (\$ MILLIONS)</i>	 6
 CHAPTER THREE: OVERVIEW	 7
OVERVIEW.....	7
THE PROMISE OF RNAI	8
<i>TABLE 1 VARIOUS TECHNOLOGIES FOR GENE SUPPRESSION</i>	8
RNAI TECHNOLOGY	9
RNAI MECHANISM: -HOW DOES IT WORK?	10
WHY SIRNA THERAPEUTICS?.....	11
SIRNA DELIVERY	12
RNAI DESIGN AND METHODS	13
Barriers to Delivery.....	14
Cellular Uptake and siRNAs.....	15
siRNA Delivery and Challenges.....	15
COMMERCIAL INTEREST	16
LIPOSOME-BASED DELIVERY	17
NONLIPOSOMAL METHODS.....	18
Nucleic-Acid Aptamers.....	18
Aptamers as Therapeutics	19
<i>TABLE 2 THERAPEUTICALLY TARGETED APTAMERS</i>	19
<i>TABLE 2 (CONTINUED)</i>	20
Aptamers for siRNA Delivery	21
Challenges-Aptamer-siRNA Delivery	22
Challenges-Aptamer-siRNA ... (Continued).....	23
Commercial Interest for Aptamers	24
ANTISENSE THERAPY.....	24
Selected Companies	25
CLASSES OF ENDOGENOUS SMALL RNAS	26
siRNA and rasiRNA	26

siRNA and rasiRNA (Continued)	27
miRNA.....	28
OUTLOOK.....	29
CHAPTER FOUR: RNAI DRUG DELIVERY	30
RNAI DISCOVERED.....	30
IMPORTANCE OF DELIVERY FOR RNAI THERAPEUTICS	31
DRUG DELIVERY TECHNOLOGIES.....	31
<i>TABLE 3 ROLE OF DRUG DELIVERY</i>	32
NEED FOR NEW TECHNOLOGIES	33
RNAI DELIVERY-TOOL FOR DRUG DISCOVERY AND DEVELOPMENT.....	33
siRNA Screening.....	34
shRNA Screening.....	34
CHALLENGES TO OVERCOME IN DELIVERING RNAI	35
<i>TABLE 4 DIFFERENT RNAI DELIVERY APPROACHES</i>	35
DIFFERENT DELIVERY TECHNIQUES.....	36
VECTOR-BASED DELIVERY.....	36
VECTOR-BASED RNAI FOR <i>IN VIVO</i> RNAI EXPERIMENTS	36
<i>TABLE 5 COMPANIES WITH PLASMID RNAI VECTORS</i>	37
Viral Vectors for Delivery of siRNA.....	37
<i>TABLE 6 RNAI VIRAL VECTOR DELIVERY METHODS</i>	38
<i>TABLE 7 LENTIVIRAL DELIVERY PRODUCTS AND COMPANIES</i>	38
NONVIRAL SIRNA DELIVERY	38
Hydrodynamic IV Injection	39
Electroporation	39
CARRIER-MEDIATED DELIVERY	39
Lipid-based siRNA Delivery.....	39
Lipid-based siRNA delivery (Continued)	40
Polymer-Based siRNA Delivery	41
Combined Lipid and Polymer Carriers for a Better siRNA Delivery.....	42
Peptide-Mediated siRNA Delivery.....	43
Antibody-Mediated siRNA Delivery	44
Dendrimer-Mediated siRNA Delivery	45
Stem-cell-based Delivery.....	45
Light Controllable Delivery of siRNA.....	45
PROPRIETARY DELIVERY PLATFORMS	46
SYSTEMIC DELIVERY STRATEGIES	47
<i>TABLE 8 THERAPEUTIC STRATEGIES</i>	48
LOCALIZED DELIVERY.....	48
Targeted Cellular Delivery.....	49
EXPRESSION-BASED STRATEGIES.....	50
RNAI DELIVERY AND IMPACT ON THERAPEUTIC DEVELOPMENTS.....	51

New Developments	52
New Developments (Continued).....	53
Tissue Delivery	54
RNAi as Drugs	55
CURRENT NONBIOLOGICAL DELIVERY VEHICLES FOR	
SIRNAS	56
Simple Excipients	56
TABLE 9 SIMPLE EXCIEPIENTS FOR RNAI DELIVERY	56
TRANSFECTION TECHNIQUES.....	57
Electroporation	57
Conjugates	57
TABLE 10 CONJUGATES, PEPTIDES, AND PROTEINS, OTHERS	57
Peptides and Proteins.....	58
Dynamic Polyconjugate Transfection	58
Polymer Carriers/Nanoparticles	58
Polymer Carriers/Nanoparticles (Continued).....	59
TABLE 11 POLYMER CARRIERS/NANOPARTICLES FOR RNAI	
DELIVERY	60
Liposomes and Lipoplexes.....	61
TABLE 12 LIPOSOMES/LIPOPLEXES AND RNAI DELIVERY	62
Case Study-siRNA in Mammalian Cells	62
Gene Silencing (RNAi) in Neuronal Cells.....	62
Concerns about RNAi Delivery	63
KEY COMPANIES	63
siRNA Transfection	63
TABLE 13 COMPANIES INVOLVED IN DRUG DELIVERY	
TECHNOLOGIES FOR SIRNA	64
Delivery as Particles or Complexes	65
Delivery with Modifications	65
SUMMARY	66
Summary (Continued).....	67
CHAPTER FIVE: RNAI-BASED THERAPEUTICS	68
RNAI-BASED THERAPEUTICS: THE EMERGING INDUSTRY	
LANDSCAPE	68
DELIVERING RNAI THERAPEUTICS	69
Delivering RNAi Therapeutics (Continued).....	70
RNAi and Cancer Therapeutics	71
REGULATORY CONCERNS	71
Regulatory Concerns (Continued).....	72
RNAI IN CLINICAL TRIALS.....	73
Clinical RNAi Pipeline	73
TABLE 14 THE GLOBAL RNA INTERFERENCE THERAPEUTIC	
PIPELINE.....	73
TABLE 14 (CONTINUED).....	74

Clinical RNAi Pipeline (Continued)	75
Clinical RNAi Pipeline (Continued)	76
THE MOST ADVANCED RNAI CANDIDATE	77
Alnylam's ALN-RSV: Respiratory Syncytial Virus	77
ALN-RSV01 Treatment of Respiratory Syncytial Virus	
Infection in Lung Transplant Patients.....	78
THERAPEUTIC RNAI-RECENT DEVELOPMENTS	79
Case Study-ALN-VSP02.....	79
Case Study-ALN-VSP02 (Continued)	80
SNALP Delivery	81
Other Candidates in Clinical Trials	82
Other Candidates in Clinical ... (Continued)	83
Unexpected Problems and Possible Solutions for RNAi-	
Based Therapies	84
Unexpected Problems and ... (Continued).....	85
CHAPTER SIX: RNAI LANDSCAPE	86
FUTURE TRENDS	86
WHAT IS RNA INTERFERENCE?.....	87
Locked Nucleic Acid.....	87
RNAI AS A RESEARCH TOOL.....	87
THE IMPORTANCE OF RNAI DESIGN.....	88
FACTS AND TIMELINES	88
MARKET GROWTH	89
GLOBAL MARKET FOR RNAI.....	89
TABLE 15 GLOBAL RNAI RESEARCH SALES AND FORECAST,	
THROUGH 2015 (\$ MILLIONS).....	90
FIGURE 1 GLOBAL RNAI RESEARCH SALES, 2008-2015 (\$	
MILLIONS).....	90
TABLE 16 GLOBAL TOTAL MARKET FOR RNAI, THROUGH 2015 (\$	
MILLIONS).....	91
FIGURE 2 GLOBAL TOTAL MARKET FOR RNAI, 2009-2015 (\$	
MILLIONS).....	91
RNAI TECHNOLOGIES/PRODUCTS IN RESEARCH	
APPLICATIONS	92
RNAi Screening for Drug Discovery	93
Individual versus Pooled siRNAs.....	94
Necessary Controls	94
High-Throughput siRNA Delivery	95
High-Throughput siRNA ... (Continued)	96
RNAI TOOL AND REAGENT MARKET	97
Transfection Products.....	97
Key Companies	98
TABLE 17 RNAI COMPANIES WITH TRANSFECTION REAGENTS.....	98
TABLE 17 (CONTINUED).....	99

RNAi Reagents	100
Lipid Transfection	101
<i>In Vivo</i> Reagents and Therapeutics.....	101
RNAi Experiments in Animals	102
RNAI AND THERAPEUTICS	103
TABLE 18 <i>IN VIVO DELIVERY</i>	104
Viral-based Transfections	105
TABLE 19 <i>VIRAL BASED DELIVERY TECHNOLOGIES</i>	106
Other Methods	106
RNAi Reagents and Kits	107
TABLE 20 <i>RNAI TOOL/REAGENT COMPANIES</i>	108
TABLE 20 (CONTINUED).....	108
KEY COMPANIES	109
Thermo Fisher	109
Thermo Fisher (Continued).....	110
Invitrogen-Results of Operations.....	111
TABLE 21 <i>INVITROGEN-REVENUES FOR THE FIRST 6 MONTHS,</i> <i>2009-2010 (MILLIONS)</i>	111
Lonza	112
TABLE 22 <i>LONZA-REVENUES, 2009 (\$ MILLIONS)</i>	113
Lonza's RNAi Products	113
THE FUTURE OF RNAI THERAPEUTICS.....	114
CHAPTER SEVEN: RNAI DRUG DELIVERY-MARKET DATA	115
MARKET SIZE AND GROWTH	115
DRUG DELIVERY TECHNOLOGIES AND MARKET.....	115
GLOBAL PHARMACEUTICAL MARKET	115
TABLE 23 <i>GLOBAL PHARMACEUTICAL SALES, THROUGH 2015 (\$</i> <i>BILLIONS)</i>	116
FIGURE 3 <i>GLOBAL PHARMACEUTICAL SALES, 2008-2015 (\$</i> <i>BILLIONS)</i>	116
UNITED STATES PHARMACEUTICAL INDUSTRY.....	117
TOP 20 PHARMACEUTICAL COMPANIES IN 2009.....	117
TABLE 24 <i>TOP 20 PHARMACEUTICAL COMPANIES, 2009 (\$</i> <i>MILLIONS: BASED ON 2008 SALES)</i>	117
TABLE 24 (CONTINUED).....	117
TABLE 25 <i>TOP 20 PHARMACEUTICAL COMPANIES, 2010 (\$</i> <i>MILLIONS: BASED ON 2009 SALES)</i>	118
TABLE 26 <i>TWELVE LARGEST PHARMACEUTICAL COMPANIES, 2010</i> <i>(\$ MILLIONS)</i>	119
DRUG DELIVERY MARKET.....	119
GLOBAL MARKET	120
TABLE 27 <i>TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES</i> <i>MARKET, THROUGH 2015 (\$ MILLIONS)</i>	120

<i>FIGURE 4 TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2009-2015 (\$ MILLIONS)</i>	121
<i>TABLE 28 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 (\$ MILLIONS)</i>	122
<i>FIGURE 5 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2009-2015 (\$ MILLIONS)</i>	122
ORAL DRUG DELIVERY	122
<i>TABLE 29 GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 (\$ MILLIONS)</i>	123
<i>FIGURE 6 GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, 2009-2015 (\$ MILLIONS)</i>	123
<i>TABLE 30 GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 (\$ MILLIONS)</i>	124
PULMONARY DRUG DELIVERY	124
<i>FIGURE 7 GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, 2009-2015 (\$ MILLIONS)</i>	125
IMPLANTABLE AND INJECTABLE DRUG DELIVERY	126
<i>TABLE 31 GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, THROUGH 2015 (\$ MILLIONS)</i>	126
<i>FIGURE 8 GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, 2009-2015 (\$ MILLIONS)</i>	126
TRANSDERMAL DRUG DELIVERY	127
<i>TABLE 32 GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 (\$ MILLIONS)</i>	127
<i>FIGURE 9 GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET, 2009-2015 (\$ MILLIONS)</i>	128
U.S. Market.....	128
<i>TABLE 33 U.S. DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 (\$ MILLIONS)</i>	128
<i>FIGURE 10 U.S. DRUG DELIVERY TECHNOLOGIES MARKET, 2009-2015 (\$ MILLIONS)</i>	129
RNAI MARKET ANALYSIS.....	129
RNAI NUCLEIC ACID DRUG DELIVERY MARKET.....	130
<i>TABLE 34 GLOBAL RNAI DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 (\$ MILLIONS)</i>	130
<i>FIGURE 11 GLOBAL RNAI DRUG DELIVERY TECHNOLOGIES MARKET, 2007-2015 (\$ MILLIONS)</i>	131
Aptamers and RNAi Market	131
<i>TABLE 35 GLOBAL APTAMERS THERAPEUTIC MARKET, THROUGH 2015 (\$ MILLIONS)</i>	132
<i>FIGURE 12 GLOBAL APTAMERS THERAPEUTIC MARKET, THROUGH 2015 (\$ MILLIONS)</i>	133
TARGETED DELIVERY.....	133
THE TOTAL NANOPARTICLE MARKET	133

<i>TABLE 36 GLOBAL NANOPARTICLE DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 (\$ MILLIONS)</i>	134
<i>FIGURE 13 GLOBAL NANOPARTICLE DRUG DELIVERY TECHNOLOGIES MARKET, 2009-2015 (\$ MILLIONS)</i>	134
<i>TABLE 37 GLOBAL TARGETED DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2015 (\$ MILLIONS)</i>	135
<i>FIGURE 14 GLOBAL TARGETED DRUG DELIVERY TECHNOLOGIES MARKET, 2009-2015 (\$ MILLIONS)</i>	135
RNAI DELIVERY APPROACHES AND CURRENT DEVELOPMENTS.....	136
DEVELOPMENT OF RNAI-BASED THERAPEUTICS.....	137
Delivery of Therapeutics to the Target Tissues.....	138
RNAi Drugs under Investigation.....	139
Naked siRNA.....	139
Companies/Latest Developments.....	140
Lipid and Polymer-Based Systems.....	141
<i>TABLE 38 LIPID-BASED TECHNOLOGIES-COMPANIES</i>	141
<i>TABLE 39 POLYMER-BASED AND LIPOSOMAL RNAI DELIVERY SYSTEMS (%)</i>	142
RNAI INTO THE PATIENTS.....	143
Polyconjugate Technologies.....	144
Polymer-Based Systems—Limitations.....	145
Nanoparticles.....	145
<i>TABLE 40 NANOPARTICLES TECHNOLOGIES-COMPANIES</i>	146
Single siRNA Delivery.....	146
<i>TABLE 41 SINGLE RNAI DELIVERY TECHNOLOGIES-COMPANIES</i>	147
NEW DELIVERY TECHNOLOGIES.....	148
SYSTEMIC DELIVERY.....	149
SYSTEMIC DELIVERY STRATEGIES.....	149
Challenges with RNAi Drug Delivery.....	150
RNAI THERAPEUTIC MARKET.....	150
<i>TABLE 42 SELECTED RNAI-BASED DRUGS IN DEVELOPMENT</i>	151
COMMERCIAL POTENTIAL OF RNAI.....	151
RNAI'S THERAPEUTIC POTENTIAL.....	151
COMPANIES AND SIRNA.....	151
How Does RNAi Work?.....	152
RNAis and Preclinical Studies.....	153
CEQ508 in Clinic.....	154
RNAi as a Therapy.....	154
GLOBAL MARKET OF THERAPEUTIC RNAI.....	155
RNAi Therapeutic Market to Play a Key Role by 2020.....	155
<i>TABLE 43 GLOBAL MARKET FOR THERAPEUTIC RNAI, THROUGH 2015 (\$ MILLIONS)</i>	156

<i>FIGURE 15 GLOBAL MARKET FOR THERAPEUTIC RNAI, 2009-2015</i> (\$ MILLIONS).....	156
<i>TABLE 44 RNAI THERAPEUTIC COMPANIES</i>	157
<i>TABLE 44 (CONTINUED)</i>	158
MicroRNA and Market.....	158
<i>TABLE 45 MICRORNA MARKET AND FORECAST, THROUGH 2015 (\$</i> <i>MILLIONS)</i>	159
<i>FIGURE 16 MICRORNA MARKET AND FORECAST, 2009-2015 (\$</i> <i>MILLIONS)</i>	159
<i>TABLE 46 TOTAL MIRNA MARKET SALES, 2008 (%)</i>	159
RNAI LICENSING DEALS	160
<i>TABLE 47 MAJOR RNAI LICENSING DEALS, 2005-2010</i>	161
<i>TABLE 47 (CONTINUED)</i>	162
Recent Trends.....	162
Recent Trends (Continued).....	163
New RNAi Delivery Technologies.....	164
TARGETED DELIVERY	164
<i>TABLE 48 SYSTEMIC DELIVERY TECHNOLOGIES-COMPANIES</i>	165
KEY THERAPEUTIC COMPANIES AND DEVELOPMENTS.....	166
<i>TABLE 49 LEAD COMPANIES DEVELOPING RNAI-BASED DRUGS</i>	167
<i>TABLE 49 (CONTINUED)</i>	167
ALNYLAM	168
<i>TABLE 50 ALNYLAM PHARMACEUTICALS-NET REVENUE, 2009 AND</i> <i>2010 (\$ THOUSANDS)</i>	169
Roche Alliance.....	169
<i>TABLE 51 ALNYLAM'S TOTAL NET REVENUES FROM RESEARCH</i> <i>COLLABORATORS, 2009 AND 2010 (\$ THOUSANDS)</i>	170
Takeda Alliance	170
Other-Discovery and Development Alliances.....	171
Isis Collaboration.....	171
Novartis Broad Alliance	172
Product Alliances.....	173
Kyowa Hakko Kirin Alliance.....	173
Cubist Alliance.....	173
Government Funding	174
NIH Contract	174
<i>TABLE 52 ALNYLAM'S DEVELOPMENT PIPELINE</i>	175
TEKMIRA.....	175
Funding.....	175
Tekmira's LNP Technology	176
<i>TABLE 53 TEKMIIRA'S DEVELOPMENT PIPELINE</i>	177
Tekmira's Pipeline.....	177
TKM-ApoB.....	177
TKM-PLK1	178

TKM-Ebola.....	179
Roche	180
Merck	180
Bristol-Myers Squibb.....	181
U.S. Army Medical Research Institute for Infectious Diseases (USAMRIID) Research Agreement	181
Takeda.....	181
Pfizer	181
<i>TABLE 54 TEKIRA'S PIPELINE.....</i>	<i>182</i>
Revenue.....	182
<i>TABLE 55 TEKIRA REVENUE (\$ MILLIONS).....</i>	<i>182</i>
RXI PHARMACEUTICALS	183
Pipeline	183
<i>TABLE 56 RXI PHARMACEUTICALS' DEVELOPMENT PIPELINE.....</i>	<i>183</i>
RXi Agreements	184
Philips.....	184
Other Collaborative Agreements.....	184
Scientific Achievements	184
NIH Grant.....	185
Financial Highlights.....	185
MARINA BIOTECH.....	185
Pipeline	186
<i>TABLE 57 MARINA BIOTECH'S DEVELOPMENT PIPELINE</i>	<i>186</i>
Revenue.....	186
<i>TABLE 58 MARINA BIOTECH REVENUE, 2008 AND 2009 (\$ THOUSANDS).....</i>	<i>187</i>
<i>TABLE 59 MARINA BIOTECH REVENUE FROM CUSTOMERS AS A PERCENTAGE OF TOTAL REVENUE, 2008 AND 2009 (%).....</i>	<i>187</i>
Ongoing Collaborations	187
Beth Israel Deaconess Medical Center-Boston, Massachusetts	187
Institut Pasteur Paris, France	188
University of British Columbia (UBC)/Vancouver Prostate Centre (VPC)-Vancouver, British Columbia, Canada	188
University of Helsinki-Helsinki, Finland	188
<i>TABLE 60 MARINA BIOTECH SELECTED COLLABORATIONS</i>	<i>188</i>
CALANDO PHARMACEUTICALS	189
CALAA-01	190
ISIS PHARMACEUTICALS	190
Pipeline	190
<i>TABLE 61 ISIS PHARMACEUTICALS DRUG DEVELOPMENT PIPELINE.....</i>	<i>191</i>
Strategic Alliances.....	191

Pharmaceutical Partners	192
<i>TABLE 62 ISIS PHARMACEUTICALS, REVENUE, 2009-2010 (\$</i>	
<i>THOUSANDS)</i>	<i>192</i>
SILENCE THERAPEUTICS	192
Proprietary Delivery Technologies	193
Pipeline	194
<i>TABLE 63 SILENCE THERAPEUTICS-DEVELOPMENT PIPELINE</i>	<i>194</i>
Collaborations	195
AstraZeneca.....	195
Dainippon Sumitomo Pharma.....	195
Quark Pharmaceuticals.....	196
Financial Highlights.....	196
<i>TABLE 64 SILENCE THERAPEUTICS-REVENUE, 2009 AND 2010 (\$</i>	
<i>MILLIONS)</i>	<i>196</i>
QUARK PHARMACEUTICALS	196
Clinical Studies.....	197
<i>TABLE 65 QUARK PHARMACEUTICALS CURRENT CLINICAL</i>	
<i>TRIALS</i>	<i>197</i>
Pipeline	197
<i>TABLE 66 QUARK PHARMACEUTICALS-DEVELOPMENT</i>	
<i>PIPELINE</i>	<i>197</i>
<i>TABLE 66 (CONTINUED)</i>	<i>197</i>
ROCHE	198
MERCK SERONO	199
SIRNAOMICS	200
ACCESS PHARMACEUTICALS.....	200
KEY MICRORNA THERAPEUTIC COMPANIES	201
MIRNA THERAPEUTICS	201
Pipeline	202
<i>TABLE 67 MIRNA-DEVELOPMENT PIPELINE</i>	<i>202</i>
REGULUS	203
Pipeline	203
Partnerships	204
LOCAL THERAPY.....	205
DRUG DELIVERY IN CANCER.....	206
RNAI MARKETPLACE CHALLENGES	207
RNAI'S GROWTH AND FUTURE.....	208
CHAPTER EIGHT: GLOBAL MARKET FOR RNAI TECHNOLOGY	209
FUTURE.....	209
RNAI- DISCOVERY AND GROWTH.....	209
RNAI THERAPEUTICS FORECAST	210
COMPANY PROFILES	210
THERAPEUTIC COMPANIES	210
Alnylam Pharmaceuticals	210

Dicerna Pharmaceuticals	211
RXi Pharmaceuticals	212
ProNAi Therapeutics	212
Somagenics	213
DELIVERY COMPANIES	213
Sirnaomics	213
Calondo Pharmaceuticals.....	214
Tacere Therapeutics	214
PhaseRx	215
Marina Biotech	215
Tekmira.....	216
Isis Pharmaceuticals	216
Silence Therapeutics	216
Quark Pharmaceuticals.....	217
Merck	218
Access Pharmaceuticals	218
AparnaBio	219
Traversa Therapeutics	219
MICRORNA COMPANIES	220
Regulus.....	220
Asuragen	220
Mirna Therapeutics	221
REAGENT/TOOL COMPANIES	221
Ambion	221
Invitrogen.....	222
B-Bridge International	222
Bio-Rad Laboratories.....	222
Clontech Laboratories	222
Cytellect	223
Dharmacon.....	223
Integrated DNA Technologies (IDT).....	224
Genecopoeia	225
GeneThera	225
Genlantis.....	225
Genosensor.....	226
General Research Laboratory	226
Imgenex.....	227
Invivogen.....	227
New England Biolabs	227
Open Biosystems	228
Origene Technologies	228
Panomics	228
Promega Corporation	229
Sigma-Aldrich	229

System Biosciences	229
COMPANY PROFILES-EUROPE	230
ACTIGENICS SA	230
AMAXA	230
Cenix Bioscience Gmbh	231
GENOVIS	231
PROSENSA HOLDING	232
QIAGEN GMBH	232
RNAX GMBH (GERMANY)	232
SANTARIS PHARMA A/S	233
COMPANY PROFILES-ASIA-PACIFIC	233
ALPHAGEN	233
BENITEC	233
BIONEER	234
CYTOPATHFINDER, INC.	234
GENESIS RESEARCH & DEVELOPMENT CORP	235
KOKEN CO. LTD.	235
ONCOLYS BIOPHARMA, INC.	235
SHANGHAI GENEPHARMA CO. LTD.	236
SHANGHAI GENOMICS	236
TRANSGENE BIOTEK	237
CHAPTER NINE: MARKET SHIFTS IN RNAI SPACE	238
MARKET SHIFTS IN RNAI SPACE	238
INTELLECTUAL PROPERTY AND PATENT ASPECTS	239
<i>TABLE 68 MAJOR RNAI COMPANIES IN THE US-PATENT</i>	
<i>DISTRIBUTION</i>	240
FUTURE DEVELOPMENTS	240
SOME SELECTED PATENTS	240
RECENT PATENT NEWS	241
Recent Patent News (Continued)	242
Recent Patent News (Continued)	243
<i>TABLE 69 PATENTS</i>	244
Recent Patent News (Continued)	245
Recent Patent News (Continued)	246
LICENSES FOR RNAI PATENTS	247
KEY COMPANIES AND PATENTS	247
ALNYLAM	247
RXI	248
ISIS	248
QUARK	249
BENITEC	249
PARTNERSHIPS, ALLIANCES, MERGERS, AND ACQUISITIONS	250
ALNYLAM COLLABORATORS: SIGNIFICANT NEW	
ADVANCES IN RNAI DELIVERY	250

Alnylam Collaborators: (Continued).....	251
Alnylam, Medtronic, and CHDI Foundation	252
Alnylam, Medtronic, and ... (Continued).....	253
Alnylam and Tekmira	254
RECENT FUNDING	255
Marina Biotech Announces Financing for up to \$8.7 Million.....	255
Tekmira and Collaborators Awarded \$2.4 Million NIH Grant for Development of RNAi Therapeutics to Treat Ebola and Marburg Viral Infections.....	256
RXi Pharmaceuticals Awarded \$1 Million in IRS Grants to Advanced RNAi Therapeutics	256
Sanofi-Aventis Completes \$10 Million Equity Investment in Regulus Therapeutics	257
Tekmira Provides Update on NASDAQ Listing.....	258
CONCLUSIONS.....	259
BIBLIOGRAPHY	260
BIBLIOGRAPHY	260
BIBLIOGRAPHY (CONTINUED)	261
BIBLIOGRAPHY (CONTINUED)	262